Issuu on Google+

___________________________________________________________________________ TARIFF | | CONDITIONS TO BE COMPLIED WITH HEADING | PRODUCT |-----------------|--------------NUMBER | | MDCs | LDCs --------------------------------------------------------------------------29.38| Glycosides, natural or re|Produced by |Produced by | produced by synthesis, and |chemical trans- |chemical trans| their salts, ethers, esters and|formation |formation | other derivatives | | | | | | | | 29.39| Vegetable alkaloids, natural or|Produced by |Produced by | reproduced by synthesis, and |chemical trans- |chemical trans| their salts, ethers, esters and|formation |formation | other derivatives | | | | | | | | 29.40| Sugars, chemically pure, other |Produced by |Produced by | than sucrose, lactose, maltose,|chemical trans- |chemical trans| glucose and fructose; sugar |formation |formation | ethers and sugar esters, and | | | their salts, other than pro| | | ducts of heading No. 29.37, | | | 29.38 or 29.39 | | | | | | | | 29.41| Antibiotics |Produced by |Produced by | |chemical trans- |chemical trans| |formation |formation | | | | | | 30.02| Human blood; animal blood pre- |Produced from |Produced from | pared for therapeutic, pro|seed for micro- |seed for micro| phylactic or diagnostic uses; |bial cultures or |bial cultures | antisera and other blood |from similar pro-|or from similar | fractions and modified |ducts of 30.02 |products of | immunological products, whether|or produced from |30.02 or pro| or not obtained by means of |materials not in-|duced from | biotechnological processes; |cluded in 30.02 |materials not | vaccines, toxins, cultures of | |included in | micro-organisms (excluding | |30.02 | yeasts) and similar products | | | | | | | | ex 31.02| Ammonium nitrate or sodium |Produced by |Produced by | nitrate, pure |chemical trans- |chemical trans| |formation |formation | | | | | |

151.


Revised Treaty of Chaguaramas